M
Mark S. Berger
Researcher at GlaxoSmithKline
Publications - 76
Citations - 9666
Mark S. Berger is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Myeloid leukemia & Gemtuzumab ozogamicin. The author has an hindex of 29, co-authored 74 publications receiving 9172 citations. Previous affiliations of Mark S. Berger include University of Malaya & Ludwig Institute for Cancer Research.
Papers
More filters
Journal ArticleDOI
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer,John K. Forster,Deborah Lindquist,Stephen Chan,C. Gilles Romieu,Tadeusz Pienkowski,Agnieszka Jagiełło-Gruszfeld,John Crown,Arlene Chan,Bella Kaufman,Dimosthenis Skarlos,Mario Campone,Neville Davidson,Mark S. Berger,Cristina Oliva,Stephen D. Rubin,S. Stein,David Cameron +17 more
TL;DR: Lapatinib plus capecitabine is superior to cape citabine alone in women with HER2-positive advanced breast cancer that has progressed after treatment with regimens that included an anthracycline, a taxane, and trastuzumab.
Journal ArticleDOI
Activity of the Dual Kinase Inhibitor Lapatinib (GW572016) against HER-2-Overexpressing and Trastuzumab-Treated Breast Cancer Cells
Gottfried E. Konecny,Mark D. Pegram,Natarajan Venkatesan,Richard S. Finn,Guorong Yang,Martina Rahmeh,Michael Untch,David W. Rusnak,Glenn M. Spehar,Robert J. Mullin,Barry R. Keith,Tona M. Gilmer,Mark S. Berger,Karl C. Podratz,Dennis J. Slamon +14 more
TL;DR: It is reported that concentration-dependent antiproliferative effects of lapatinib were seen in all breast cancer cell lines tested but varied significantly between individual cell lines with up to 1,000-fold difference in the IC(50)s (range, 0.010-18.6 micromol/L).
Journal ArticleDOI
Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse
Eric L. Sievers,Richard A. Larson,Edward A. Stadtmauer,Elihu H. Estey,Bob Löwenberg,Hervé Dombret,Chatchada Karanes,Matthias Theobald,John M. Bennett,Matthew L. Sherman,Mark S. Berger,Catharine B. Eten,Michael R. Loken,Jacques J. M. Van Dongen,Irwin D. Bernstein,Frederick R. Appelbaum +15 more
TL;DR: Administration of the antibody-targeted chemotherapy agent Mylotarg to patients with CD33-positive acute myeloid leukemia in first relapse induces complete remissions with what appears to be a favorable safety profile.
Journal Article
Correlation of c-erbB-2 Gene Amplification and Protein Expression in Human Breast Carcinoma with Nodal Status and Nuclear Grading
Mark S. Berger,Gottfried W. Locher,S. Saurer,William J. Gullick,Michael D. Waterfield,Bernd Groner,Nancy E. Hynes +6 more
TL;DR: This is the first study showing that a determination of the level of c-erbB-2 protein in paraffin-embedded tumor sections may have prognostic value for the course of human breast cancer.
Journal ArticleDOI
Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate.
Eric L. Sievers,F R Appelbaum,R.T. Spielberger,Stephen J. Forman,David A. Flowers,Franklin O. Smith,K. Shannon-Dorcy,Mark S. Berger,Irwin D. Bernstein +8 more
TL;DR: In a dose escalation study, 40 patients with relapsed or refractory CD33 + acute myeloid leukemia (AML) were treated with an immunoconjugate (CMA-676) consisting of humanized anti-CD33 antibody linked to the potent antitumor antibiotic calicheamicin this paper.